The National Pharmaceutical Pricing Authority (NPPA) on 6th August 2021 has fixed the ceiling price of 6 scheduled formulations under Drug Prices Control Order 2013. The retail price is applicable only to the individual manufacturer / marketer i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
The formulations include Budesonide Respule, Paracetamol + Caffeine Tablet, Metoprolol Succinate (ER) + Cilnidipine + Telmisartan Tablet, Metoprolol Succinate (ER) + Cilnidipine + Telmisartan Tablet, Atorvastatin + Ezetimibe Tablet and Cefixime + Potassium Clavulanate tablet.
As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
